What is Norgine?
Founded in 1906 and headquartered in The Netherlands, Norgine stands as a prominent European specialist pharmaceutical company. With over a century of experience, Norgine has built a robust reputation for bringing innovative and life-changing medicines to market. Its focus on specialist pharmaceuticals suggests a strategic approach to niche therapeutic areas, aiming to address unmet medical needs and improve patient outcomes. The company's long-standing operational history and deep-rooted expertise position it as a key player in the European pharmaceutical landscape, capable of navigating complex regulatory environments and market dynamics.
How much funding has Norgine raised?
Norgine has raised a total of $12.1M across 1 funding round:
Other Financing Round
$12.1M
Other Financing Round (2016): $12.1M, investors not publicly disclosed
What's next for Norgine?
The recent enterprise-level investment, though undisclosed in amount, signals a pivotal moment for Norgine. This infusion of capital is likely earmarked for accelerating growth, expanding its product pipeline, and potentially broadening its geographical reach. Given Norgine's long history and established market position, this financing round could support strategic acquisitions, further research and development into novel therapies, or enhancements to its manufacturing and distribution capabilities. The company's trajectory suggests a continued focus on innovation and patient-centric solutions, leveraging this new backing to solidify its leadership in specialist pharmaceuticals.
See full Norgine company page
